

Development of Genetically Encoded Biosensors for Reporting the Methyltransferase-Dependent Biosynthesis of Semisynthetic Macrolide Antibiotics

Yiwei Li, Megan Reed, H. Tonie Wright, T. Ashton Cropp, and Gavin J. Williams*



Cite This: *ACS Synth. Biol.* 2021, 10, 2520–2531



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Clarithromycin is an improved semisynthetic analogue of the naturally occurring macrolide, erythromycin. The subtle modification of a methyl group on the C-6 hydroxyl group endows the molecule with improved acid stability and results in a clinically useful antibiotic. Here, we show that the effector specificity of the biosensor protein, MphR, can be evolved to selectively recognize clarithromycin and therefore report on the production of this molecule *in vivo*. In addition, a crystal structure of the evolved variant reveals the molecular basis for selectivity and provides a guide for the evolution of a new metabolic function using this biosensor.

KEYWORDS: macrolide, polyketide, biosensor, transcription factor, synthetic biology



INTRODUCTION

Macrolides are a large class of natural products that display potent biological activities that span many therapeutic areas.¹ The core structures of macrolides are biosynthesized by large, modular enzymes known as polyketide synthases (PKSs).^{2,3} The prototypical macrolide antibiotic, erythromycin A (ErA), while clinically useful, has the limitations of acid instability and limited bioavailability.⁴ Clarithromycin (CLA), a second-generation macrolide antibiotic derived from ErA (Figure 1A), effectively addresses these limitations, while also expanding the scope of activity to other microorganisms not impacted by ErA.^{4–12} Moreover, CLA has served as a platform for the synthesis and derivatization of ketolide antibiotics including telithromycin and solithromycin (Figure 1B).^{13–18} CLA and ErA differ at the C6-position of the macrolactone core: the C6-hydroxyl group in ErA is replaced with a methoxy group in CLA. Currently, CLA is produced through semi-synthesis in a six-step sequence from ErA, including protection, methylation, and deprotection.¹⁹ Despite the fact that ErA is produced by fermentation on a massive scale (4000 metric tons annually),²⁰ semi-synthesis is costly and produces a substantial amount of chemical waste products.^{21,22} Moreover, given that the essential C6 O-methylation is also a key functional group of many later-generation macrolide antibiotics, strategies to improve the efficiency and yield of this modification are highly sought after.

A potential route to O-methylated macrolides involves the regiospecific methylation of ErA (Figure 1A), which coupled with ErA biosynthetic machinery,^{23,24} could furnish an

engineered microbial strain programmed for the manufacture of CLA or related derivatives. However, methyltransferases (MTs) with the desired specificity are not currently known. It is not yet practical to search the massive pool of MTs and to characterize their substrate specificities *via* traditional low throughput or computational approaches. Similarly, while directed evolution^{25,26} could address our limited ability to rationally reprogram MT specificity, high-throughput tools are not available to identify improved MT variants while searching through large mutant libraries. Screens or selections for many polyketide biosynthesis steps are not available or are not adaptable to *in vivo* experiments. This evaluation bottleneck could be eliminated by leveraging a genetically encoded biosensor that reports the conversion of ErA to CLA *in vivo*. Biosensors based on transcription factors have been developed for a wide range of small molecules including phenylpropanoids, steroids, and lactams,²⁷ but none are currently available for the selective detection of CLA.

The repressor protein MphR controls the deactivation of ErA by regulating the transcription of the ErA resistance gene *mphA*, encoding a macrolide 2'-phosphotransferase.²⁸ The

Received: April 9, 2021

Published: September 21, 2021






Figure 1. Erythromycin derivatives as antibiotics and their detection by the macrolide sensing transcription factor MphR. (A) Chemical conversion of ErA to CLA. In principle, this could be carried out in a single step with a suitable MT. (B) Structures of semi-synthetic antibiotics derived from CLA. (C) Scheme illustrating the MphR macrolide biosensor. In the presence of a macrolide effector (hexagon) and MphR, MphR undergoes a conformational change and leaves the operator sequence, allowing the transcription of the downstream reporter, *gfp*. For clarity, the phosphorylation of ErA via MphA (housed in pJZ12) is omitted from the figure. (D) Ligand binding site of wild-type MphR (monomer A, PDB: 3FRQ) with two key residues and a water molecule (teal sphere) surrounding the C6-OH of ErA shown (green sticks) and labeled.

protein, a member of the TetR class of repressor proteins, binds to a DNA operator, but in the presence of a small-molecule effector ligand it releases DNA allowing for transcription to take place. MphR is de-repressed by other macrolides, including CLA, oleandomycin, azithromycin, roxithromycin, and others.^{29–31} The MphR gene cassette has been redesigned to control a green fluorescence protein (GFP) reporter in *Escherichia coli* in response to macrolides (Figure 1C).^{29,32} The sensitivity and specificity of MphR have been tuned by directed evolution.²⁹ Accordingly, it was hypothesized that given the ability of MphR to be efficiently de-repressed by both ErA and CLA that this inherent promiscuity could be leveraged by directed evolution to provide a MphR variant with specificity toward CLA. A variant biosensor system that is de-repressed in the presence of CLA but not ErA (or vice versa) provides a potential platform for the discovery and directed evolution of a MT for the biocatalytic synthesis of C6-methylated macrolides.

Herein, a genetically encoded biosensor capable of reporting the conversion of ErA to CLA was engineered. Inspired by rare examples^{33–35} that engineer the transcription factor ligand specificity by combining rational design and directed evolution strategies, a structure-guided mutagenesis followed by random mutagenesis and gene circuit engineering was developed to engineer the MphR-based sensor. This led to the identification of a quadruple MphR mutant dubbed “M9C4” that can discriminate between ErA and CLA. Extensive mutagenesis

and structural studies enabled the contribution of each mutation to the specificity of M9C4 to be elucidated, suggesting a rationale for the emergence of exquisite effector selectivity.

RESULTS

Structure-Guided Mutagenesis of MphR to Provide a CLA Specific Biosensor. Previously, it has been demonstrated that wild-type MphR does not discriminate between ErA and CLA.²⁹ The structure of MphR bound with ErA reveals that Arg122 and Asn123 are involved in hydrogen bonding interactions with water molecules within the effector binding pocket and with the ErA C6-OH (Figure 1D).²⁸ It was envisioned that the disruption of this H-bonding network by mutagenesis at Arg122 or Asn123 may negatively impact the ability of MphR to bind ErA and concomitantly provide more space for the C6-O-methyl group of CLA. In addition, the sequence of amino acids from Arg133 to Ala140 is a part of a turn that connects the two helices that accommodate the macrolide (Figure 1D). Inserting an amino acid into this turn might create flexibility and space for the additional C6-O-methyl of CLA. To test these hypotheses, saturation mutagenesis of Arg122 and Asn123 was carried out, resulting in 19 possible variants at each residue, and the mutant Gly137insAla was constructed. Unique mutants from the Arg122X and Asn123X libraries were identified by DNA




Figure 2. Characterization of MphR biosensor variants with engineered ErA/CLA specificity. (A) Wild-type MphR dose–response curves. (B) MphR variant R122T dose–response curves. (C) MphR variant R122V dose–response curves. (D) MphR variant M1B10 dose–response curves. (E) MphR variant M9C4 dose–response curves. (F) MphR variant M9C4* dose–response curves. Error bars represent the standard error of the mean ($n = 3$) and are only visible when larger than the data point symbol.

sequencing. The corresponding biosensor strains, consisting of the plasmids pMLGFP and pJZ12 (Figure 1C), were screened at a fixed concentration of ErA and CLA to determine their specificity, along with the Gly137insAla mutant (Supporting Information, Figure S1). Of the mutations tested, only R122V and R122T displayed a potential change in effector specificity compared to the wild-type MphR biosensor, supporting 2.7- and 2.8-fold increased reporter fluorescence, respectively, with CLA compared to ErA. A possible explanation for this specificity is that the substitution of Arg122 with valine or threonine accommodates the increased bulk of the C6-O-methyl group of CLA and disturbs the hydrogen bonding between MphR and the ErA C6-OH. Notably, every substitution at Arg122 tested drastically decreased the sensitivity of MphR with ErA compared to the wild-type, possibly due to a critical salt bridge between Arg122 and Glu109 (Supporting Information, Figure S2). Interestingly, substitutions at Asn123 were better tolerated, as judged by the fluorescence response of the biosensor strains with ErA and CLA. However, none of the Asn123X library members displayed an improvement in specificity toward CLA, compared to the wild-type biosensor strain.

To further characterize the R122V and R122T biosensor strains, the GFP fluorescence of each mutant in the presence of various concentrations of CLA and ErA was determined. The biosensor performance characteristics were extracted by fitting the dose response data to the Hill equation (Figure 2A–C and Table 1, entries 1–3). The dose–response curves of the two mutants R122V and R122T were very different from that of the wild-type biosensor strain. In fact, for each mutant, the normalized fluorescence is higher with CLA than with ErA at every effector concentration tested, indicating significant changes in effector specificity. Compared to the wild-type, the sensitivity ($K_{1/2}$) and dynamic range of the two mutants toward each macrolide were poorer, perhaps due to the disturbance of the salt bridge between Arg122 and Glu109. Additionally, reduced sensitivity toward ErA might be due to the disruption of a hydrogen bonding network between ErA C6-OH, a water molecule, Arg122, and Asn123 (Figure 1D). Nevertheless, the similarity of Hill coefficients between mutants and the wild-type indicates that the degree of positive cooperativity has not been affected by the mutations. Notably, the R122T and R122V mutations shift selectivity toward CLA ~ 2 - and ~ 4 -fold, respectively, compared to the wild-type

Table 1. Performance Features of Wild-Type and Mutant MphR Biosensor Strains

entry	biosensor	mutations ^a	effector	$K_{1/2}$ (μ M) ^b	dynamic range ^c	n^d	selectivity ^e
1	wild-type ^f		ErA	1.54 $\pm$ 0.03	51,491	3.39 $\pm$ 0.13	0.93 $\pm$ 0.03
			CLA	1.65 $\pm$ 0.05	51,143	2.31 $\pm$ 0.17	
2	R122T ^f	R122T	ErA	45.22 $\pm$ 1.42	5078	2.54 $\pm$ 0.17	2.06 $\pm$ 0.13
			CLA	21.96 $\pm$ 1.15	6574	2.48 $\pm$ 0.28	
3	R122V ^f	R122V	ErA	145.40 $\pm$ 37.82	300	5.24 $\pm$ 4.10	4.61 $\pm$ 1.23
			CLA	31.56 $\pm$ 1.95	4807	2.39 $\pm$ 0.34	
4	M9C4 ^f	R122T, K132N, A151T, H184Q	ErA	68.32 $\pm$ 1.65	12,892	2.01 $\pm$ 0.06	7.91 $\pm$ 0.42
			CLA	8.64 $\pm$ 0.41	36,012	1.61 $\pm$ 0.08	
5	M1B10 ^g	T49I, L89V, D98N, E109D	ErA	43.62 $\pm$ 0.85	11,559	1.98 $\pm$ 0.06	4.19 $\pm$ 0.16
			CLA	10.41 $\pm$ 0.33	22,643	2.45 $\pm$ 0.16	
6	R122T/K132N ^g	R122T, K132N	ErA	25.52 $\pm$ 1.01	12,007	2.18 $\pm$ 0.16	1.77 $\pm$ 0.09
			CLA	14.40 $\pm$ 0.44	13,923	2.15 $\pm$ 0.14	
7	R122T/A151T ^g	R122T, A151T	ErA	71.77 $\pm$ 3.43	4126	2.61 $\pm$ 0.16	5.88 $\pm$ 0.36
			CLA	12.21 $\pm$ 0.48	21,985	2.18 $\pm$ 0.17	
8	R122T/K132N/A151T ^g	R122T, K132N, A151T	ErA	45.26 $\pm$ 1.69	13,506	2.27 $\pm$ 0.12	5.37 $\pm$ 0.38
			CLA	8.43 $\pm$ 0.50	38,308	1.64 $\pm$ 0.13	
9	M9C4* ^g	R122I, K132N, A151T, H184Q	ErA	163.70 $\pm$ 36.52	1876	1.35 $\pm$ 0.18	12.42 $\pm$ 2.79
			CLA	13.18 $\pm$ 0.36	35,175	2.04 $\pm$ 0.10	
10	M9C4-A3 ^g	R122T, K132N, A151T, H184Q + <u>GGAAGGT</u>	ErA	37.77 $\pm$ 3.18	10,984	4.41 $\pm$ 0.88	7.71 $\pm$ 0.59
			CLA	6.62 $\pm$ 0.44	51,252	1.26 $\pm$ 0.07	
11	M9C4-E7 ^g	R122T, K132N, A151T, H184Q + <u>AGATGGT</u>	ErA	37.58 $\pm$ 1.57	13,418	2.26 $\pm$ 0.19	7.21 $\pm$ 0.59
			CLA	5.21 $\pm$ 0.37	45,331	1.69 $\pm$ 0.16	
12	M9C4-H4 ^g	R122T, K132N, A151T, H184Q + <u>AGAAGGC</u>	ErA	49.38 $\pm$ 0.97	12,809	2.05 $\pm$ 0.08	6.13 $\pm$ 0.34
			CLA	8.05 $\pm$ 0.42	48,381	1.46 $\pm$ 0.08	
13	M9C4-E7 (2-plasmid strain w/ EryG) ^h	R122T, K132N, A151T, H184Q + <u>AGATGGT</u>	ErA	16.30 $\pm$ 0.98	70,063	1.76 $\pm$ 0.13	17.16 $\pm$ 2.73
			CLA	0.95 $\pm$ 0.14	97,213	1.82 $\pm$ 0.48	
14	M9C4-E7 (1-plasmid strain w/ EryG) ⁱ	R122T, K132N, A151T, H184Q + <u>AGAAGGT</u>	ErA	14.03 $\pm$ 2.11	43,501	1.96 $\pm$ 0.42	15.94 $\pm$ 2.90
			CLA	0.88 $\pm$ 0.09	64,900	2.69 $\pm$ 0.69	

^aFor ribosome binding site (RBS) mutants, the RBS sequence is shown, mutated nucleotides are underlined. ^bConcentration of the ligand at half-maximum normalized GFP fluorescence. ^cGFP_{max} – GFP_{min}. ^dHill coefficient, a measure of cooperativity within the MphR biosensor. Values > 1 indicate positive cooperativity. ^eRatio of $K_{1/2}$ (CLA)/ $K_{1/2}$ (ErA). ^fTwo plasmid system consisting of pMLGFPK/pJZ12. ^gTwo plasmid system consisting of pSense-MphR-MphA/pCOLADuet-EryG. ^hTwo plasmid system consisting of pSense-MphR-MphA-EryG. ⁱOne plasmid system consisting of pSense-MphR-MphA-EryG.

biosensor strain, as judged by the ratio of $K_{1/2}$'s for each effector. Although these mutants are a good first step toward a CLA-specific biosensor, their relatively small dynamic range and poor selectivity needed to be further addressed.

Directed Evolution of MphR Mutants. It is difficult to predict which additional residues to target for mutagenesis to further improve the effector selectivity of MphR. Accordingly, a directed evolution approach was explored. Three error-prone PCR mutant libraries of MphR were constructed using wild-type, R122T, and R122V MphR as each template. Flow cytometry was first used to enrich the population of mutants that were induced poorly by ErA by collecting ~5% of each library with the lowest fluorescence (Supporting Information, Figure S3). Next, those clones were screened in microplates either in the presence of CLA, ErA, or no macrolide to establish their macrolide specificity. Based on this two-tier screening strategy, two mutants were selected for further analysis: "M9C4" from the error-prone library based on R122T and "M1B10" from the error-prone library based on the wild-type MphR.

Subsequently, ErA/CLA dose–response curves of M9C4 and M1B10 were determined (Figure 2D,E and Table 1,

entries 4 and 5, respectively). Notably, the $K_{1/2}$ of M9C4 with ErA and CLA is increased 45- and 5-fold, respectively, compared to the wild-type, resulting in a variant that is ~8-fold more selective for CLA versus ErA. Additionally, M9C4 displays a 2.8-fold higher dynamic range with CLA than with ErA. Similarly, the $K_{1/2}$ of M1B10 with ErA and CLA are increased by 29- and 6.3-fold, respectively, compared to the wild-type, resulting in a variant that is ~4-fold more selective for CLA versus ErA. However, M1B10 displays only a 2-fold higher dynamic range with CLA than with ErA. The DNA sequences of each variant revealed four amino acid changes: T49I, L89V, D98N, and E109D for M1B10 and R122T, K132N, A151T, and H184Q for M9C4. In addition, the sequence of M9C4 also revealed a non-coding mutation between the *mphR* promoter and its RBS (Supporting Information, Table S1). Both R122T and K132N are located in the ligand binding domain of MphR, while A151T and H184Q are located in the regulatory core that forms the dimerization interface. Given that the selectivity and dynamic range of M9C4 was superior to those of M1B10, M9C4 was chosen as the template for mutational analysis.

Mutational Analysis of MphR M9C4. To establish which mutations contributed to the CLA selectivity of M9C4, all possible single (4), double (6), and triple (4) mutants were generated by site-directed mutagenesis, in addition to a mutant which only contained the non-coding mutation. Each variant biosensor strain was then assayed at fixed concentrations of ErA and CLA (Figure 3). Notably, the specificity of the non-




Figure 3. Activities of individual and combined mutations from M9C4 using 5 μ M ErA and CLA. NCR, non-coding region mutant. Error bars represent the standard error of the mean ($n = 3$).

coding MphR variant was indistinguishable from that of the wild-type (“NCR”, Figure 3), indicating that the nucleotide mutation in the non-coding region is not responsible for the CLA specificity of M9C4.

Turning to the amino acid mutation of the four single mutants, R122T is the only mutation that affects the specificity between CLA and ErA, while K132N, A151T, and H184Q were indistinguishable from the wild-type MphR biosensor. However, the combination of K132N or A151T with R122T (R122T/K132N and R122T/A151T) further shifts specificity toward CLA and suggests that M9C4 may derive most of its selectivity from these three mutations (Figure 3). The combination of R122T and H184Q is indistinguishable from R122T alone. Furthermore, the double mutants that lack R122T (K132N/A151T, K132N/H184Q, and A151T/H184Q) are indistinguishable from wild-type MphR. Together, the single and double mutant data support the importance of the semi-rational R122T mutation in combination with some of those derived from random mutagenesis. Dose–response curves show that R122T in combination with K132N or

A151T improves the MphR biosensor properties in different respects (Table 1 and Supporting Information, Figure S4). For example, compared to R122T, the double mutant R122T/K132N appears to improve the dynamic range with CLA ~ 2 -fold. Both the dynamic range with CLA and the CLA/ErA selectivity of the R122T/A151T mutant improve ~ 3 -fold compared to R122T. As anticipated by these results, the combination of R122T, K132N, and A151T into the corresponding triple mutant results in a mutant MphR biosensor strain with the highest dynamic range and selectivity for CLA compared to any of the parent single and double mutants (Figure 3). Interestingly, even though H184Q did not seem to contribute significantly to the CLA selectivity of the double or triple mutants, inclusion in M9C4 does improve selectivity 1.5-fold compared to R122T/K132N/A151T, largely through increasing the $K_{1/2}$ for ErA (Table 1).

The importance of R122T in the triple mutant, coupled with the incomplete coverage of the original R122X saturation library (Supporting Information, Figure S1), prompted testing of another substitution in M9C4. Given its similarity to threonine (valine was already tested as a single substitution, entry 3, Table 1), isoleucine was introduced at Arg122 in the quadruple mutant M9C4, generating M9C4* (entry 9, Table 1). Compared to M9C4, the dynamic range of this new quadruple amino acid mutant (R122I/K132N/A151T/H184Q) toward ErA decreased ~ 7 -fold, while toward CLA it was unchanged. As anticipated, selectivity of this new quadruple amino acid mutant was improved 1.5-fold, compared to M9C4 (Figure 2 and Table 1). Although the selectivity of M9C4* was improved on the basis of the $K_{1/2}$ for each macrolide, the $K_{1/2}$ (CLA) of M9C4* was 1.5-fold higher than the parent M9C4. Consequently, the sensitivity of M9C4 at lower concentrations of CLA is better than that of M9C4*, with no de-repression by ErA up to $\sim 10 \mu$ M ErA. Thus, M9C4 was chosen to be further investigated.

Validation of the Simulated Conversion of ErA to CLA via MphR M9C4. The low $K_{1/2}$ of M9C4 for CLA, its lack of de-repression by ErA up to 10μ M, and its large dynamic range could enable a sensitive interrogation of the bioconversion of ErA to CLA in living cells. Initially, in the presence of an active MT, the ErA concentration would be high (e.g., at 0% conversion), while after some time, the concentration of ErA would decrease in proportion to the increase in the concentration of CLA. Because an enzyme to effect the conversion of ErA to clarithromycin is not yet available, to




Figure 4. Fluorescence response of the wild-type and M9C4 mutant MphR biosensor strains with mixtures of ErA/CLA simulating their conversion. (A) Total concentration of ErA/CLA is 10μ M such that 0% conversion represents 10μ M ErA and 100% conversion represents 10μ M CLA. Error bars represent the standard error of the mean ($n = 7$) and are only visible when larger than the data symbol. (B) Student’s unpaired two-tailed t -test indicated $p < 0.0001$ between 0 and 10% simulated conversion.




Figure 5. Fluorescence response of various two and one-plasmid MphR biosensor strains with mixtures of ErA/CLA simulating their conversion. (A) Two-plasmid system pSense-M9C4-E7-MphA/pCOLADuet-EryG dose–response curves. Error bars represent the standard error of the mean ($n = 3$) and are only visible when larger than the data point symbol. (B) One-plasmid system pSense-M9C4-E7-MphA-EryG dose–response curves. Error bars represent the standard error of the mean ($n = 3$) and are only visible when larger than the data point symbol. (C) pSense-M9C4-E7-MphA-EryG (red) and pSense-MphR-MphA-EryG (black) were screened with different combinations of ErA and CLA. Error bars represent the standard error of the mean ($n = 7$) and are only visible when larger than the data point symbol. (D) Student's unpaired two-tailed t -test indicated $p < 0.05$ between 0 and 2% simulated conversion. Error bars represent the standard error of the mean ($n = 7$) and are only visible when larger than the data symbol.

mimic the bioconversion, different ratios of ErA and CLA were applied as a mixture to the cultures of the wild-type and M9C4 biosensor strains and the GFP outputs were determined (Figure 4A). Gratifyingly, the GFP output of the M9C4 biosensor strain is linear across the entire range of macrolide mixtures tested, while the wild-type response was not strongly correlated. Additionally, M9C4 was able to differentiate as low as 10% conversion of ErA to CLA (equivalent to 1 μ M or 0.748 μ g/mL CLA) as mimicked by these assay conditions (Figure 4B). This confirms that the M9C4 biosensor strain is an effective reporter to validate the ability of a MT to biosynthesize CLA from ErA, with the caveat that the conversion needs to reach 10%.

Improving the CLA Sensitivity of MphR M9C4.

Mutagenesis of the RBS region of MphR M9C4 was expected to enhance the sensitivity toward CLA (and ErA) by modulating the expression of the regulatory protein. Three previously described RBS sensitivity mutants²⁹ were introduced into M9C4 (Supporting Information, Table S2) and their dose–response with ErA and CLA determined (entries 10–12, Table 1; Supporting Information, Figure S5). Gratifyingly, the $K_{1/2}$ of all three mutants with both ErA and CLA decreased, in comparison to that of M9C4, demonstrating that the incorporation of the RBS mutants into the M9C4 mutant improved sensitivity toward both macrolides. Notably, the CLA sensitivity of M9C4-E7 was the most improved of the three variants (1.7-fold, compared to M9C4) and its dynamic range for CLA was improved by 1.3-fold compared to M9C4.

Collectively, these data suggest that M9C4-E7 is more suitable for screening the conversion of ErA to CLA at lower concentrations of macrolides compared to M9C4.

Prototype *In Vivo* System for Screening MT Candidates. At this point, the biosensor strain consists of two plasmids, pMLGFP(K) and pJZ12, that both house the biosensor components. As a preliminary step toward the construction of a single *E. coli* strain capable of screening libraries of MT variants, two new plasmids were constructed: one that housed all of the biosensor components in one place (pSense-M9C4-E7-MphA) and another that carried a potential candidate MT gene (pCOLADuet-EryG) (Supporting Information, Figure S6 and Table S2). Given that an MT capable of converting ErA to CLA is not yet known, eryG, responsible for the conversion of Erythromycin C (ErC) to ErA in *Sporocladopsis erythraea*, was used as a proxy to determine the detection characteristics of the prototype biosensor strain.^{36,37} Importantly, EryG does not methylate ErA or CLA (data not shown), so exogenous mixtures of ErA/CLA will not be modified in the presence of this MT. Notably though, the conversion of ErC to ErA was detected by LC–MS analysis of the culture medium after feeding ErC into a biosensor strain containing pCOLADuet-EryG, indicating that this system is competent for the MT expression (Supporting Information, Figure S7). In addition, even with the potential metabolic burden of hosting two plasmids, the two-plasmid strain containing pSense-M9C4-E7-MphA/pCOLADuet-EryG maintained and even enhanced the selectivity of CLA over ErA ~2-




Figure 6. Interactions of MphR and the macrolide effector. (A) Effector binding site of wild-type MphR with bound ErA (yellow sticks). Select water molecules are shown (cyan spheres). Polar contacts within 4 Å of ErA are shown as dotted lines. Hydrogen bonding between the C6-OH (asterisk) of ErA and Arg122 in wild-type MphR is mediated by a water molecule. (B) Effector binding site of M9C4 with bound CLA (yellow sticks). Select water molecules are shown (cyan spheres). Polar contacts within 4 Å of CLA are shown as dotted lines. The CLA C6-OME is highlighted with an asterisk. Protein Data Bank accession code 6U18.

fold as well as increased the sensitivity of ErA and CLA by ~ 2.3 and ~ 5.5 fold, respectively, compared to the parent strain (entry 13 vs 11, Table 1; Figure 5A). In order to reduce the metabolic load of this two-plasmid system and to improve the transformation efficiency of potential MT libraries into the host as part of the screening procedure, *eryG* was integrated into the biosensor plasmid to furnish the one-plasmid system, pSense-M9C4-E7-MphA-EryG (Supporting Information, Figure S6). Notably, the identity of the RBS and promoter sequence driving the EryG expression in this one plasmid system proved critical for the proper expression of the MT. For example, a calculated RBS sequence and the original promoter from pSense proved insufficient to drive the EryG expression, as judged by LC–MS analysis of the conversion of ErC to ErA (pSense-1, Supporting Information, Figure S8), whereas the RBS sequence from pET28a (AAGGAG) and the strong T7 promoter was able to support a 16-fold higher conversion of ErC to ErA than the initial strain (pSense-3, Supporting Information, Figure S8). The sensitivity and selectivity of the one-plasmid biosensor strain optimized for the MT expression (AAGGA RBS and T7 promoter) was indistinguishable from the corresponding 2-plasmid system (entries 13 vs 14, Table 1; Figure 5B), albeit with a concomitant $\sim 67\%$ reduction in the dynamic range for CLA. The one-plasmid system response retained the linear relationship with the proportion of CLA in the two macrolide combination (Figure 5C). However, the detection capabilities of this system with mixtures of ErA/CLA

that simulate the conversion of ErA to CLA now reflect the improved $K_{1/2}$ for CLA, as low as 2% conversion of ErA to CLA (equivalent to 0.2 μM or 0.15 $\mu\text{g/mL}$ CLA) can be detected (Figure 5D).

Structure of MphR M9C4 Bound with CLA. To understand the molecular basis of CLA selectivity in M9C4, we expressed and purified the variant as a hexa-histidine tag fusion protein for crystallographic structure determination. The protein was purified to homogeneity through a sequential process that yielded the protein without tags and containing a glycine residue in the N-terminal position (Supporting Information, Figure S9). The purified protein was then mixed with CLA and subjected to high throughput screening of crystallization conditions. Several conditions produced crystals with the best diffracting to 2 Å resolution. The structure validated the early hypothesis that R122T is an important mutation that contributes to MphR specificity. The replacement of Arg122 (Figure 6A) in the wild-type MphR with threonine in the M9C4 structure (Figure 6B) shifts the location of a water molecule that originally hydrogen bonded to ErA C6-OH in the wild-type MphR structure. It also leaves the carboxylate of Glu109 (which is paired with the guanidine group of Arg122 in wild-type MphR) unliganded in the mutant structure—buried in the protein and potentially destabilizing to the overall structure unless protonated, as it may be at the pH of the crystal. Notably, the A151T mutation is in proximity to the structural changes that accompany the R122T mutation,




Figure 7. Trajectory of MphR engineering toward a CLA-selective biosensor. Relative size of bubble, dynamic range ($\text{GFP}_{\max} - \text{GFP}_{\min}$). Red bubbles, variants that were used in subsequent rounds. Gray bubble, variants that were not used in subsequent rounds. Solid arrows, saturation mutagenesis. Dashed arrows, error-prone PCR. Dotted arrows, non-coding mutagenesis. Selectivity (CLA/ErA), $\text{ratio of } K_{1/2}(\text{CLA})/K_{1/2}(\text{ErA})$.

and the A151T substitution may play a role in facilitating the reorganization of water that appears to favor the binding of CLA by M9C4. Consistent with this, the R122T/A151T double mutant is the most CLA selective of those tested (Figure 3). Other than these subtle changes, the M9C4 structure is overall closely similar to that of the wild-type MphR structure bound to ErA. This suggests that very small structural and possibly dynamic changes can result in significant ligand binding preferences.

DISCUSSION

Genetically encoded biosensors based on transcription factors offer enormous potential as high-throughput screening tools to report a variety of natural product biosynthetic transformations.^{38,39} However, transcription factors with the required effector specificity are often not available. For example, to accurately detect a post-PKS tailoring step, a biosensor needs to distinguish the tailored natural product from the non-modified intermediate. Here, the effector promiscuity of the macrolide sensing MphR was leveraged as a platform to construct an MphR variant that can detect the methylation of ErA, thereby providing a biosensor for screening the activities of MTs that can convert ErA to CLA. The wild-type MphR is de-repressed by both ErA and CLA, providing a platform for creating a CLA selective variant that is poorly de-repressed by ErA yet retains the ability to be induced by CLA at concentrations that are likely relevant for screening libraries of MT variants. This was accomplished *via* the combined application of structure-guided mutagenesis and directed evolution approaches to shift the specificity of MphR toward CLA (Figure 7). The full characterization of each variant at each stage enabled a complete evaluation of the suitability of each newly identified mutation and helped inform the overall engineering process. Saturation mutagenesis at Arg122 yielded two variants, R122T and R122V, which were sufficiently improved to be used to parent libraries of random mutants *via* error-prone PCR, along with the wild-type MphR,

with the goal of identifying additional mutations that could improve the selectivity and dynamic range in an additive or synergistic manner. Gratifyingly, this afforded two CLA-selective variants, M9C4 (derived from R122T) and M1B10 (derived from wild-type MphR), each with four amino acid mutations compared to wild-type. The selectivity and dynamic range of M9C4 was superior compared to those of M1B10, suggesting that the initial structure-guided mutations might be critical for providing a minimum level of selectivity and dynamic range identified from the two-tiered flow cytometry–microplate screening strategy (Figure 7). Furthermore, R122T was likely a better starting point than R122V, possibly due to its improved dynamic range, given that improved variants were not identified from the mutant library based on R122V. Remarkably, all four mutations in M9C4 are necessary for the maximum CLA/ErA selectivity (Figure 3), even though three of the four mutations were introduced in a single step from the error-prone PCR mutagenesis. As dictated by the structure-based redesign, the R122T mutation is the major contributor to altering selectivity, while K132N improves the dynamic range and A151T and H184Q improve selectivity to some extent.

The crystal structure of M9C4 with bound CLA verifies the critical role of R122T (Figure 6). The substitution of Thr at Arg122 clearly reorganizes the effector binding site of MphR and likely creates space for the C6-methoxy group of CLA to be accommodated. In addition, A151T potentially also plays a role in this structural reorganization, providing an explanation for its appearance in the quadruple mutant, M9C4. However, the structure alone cannot provide a complete explanation for the ability of M9C4 to discriminate CLA and ErA. The mutations in M9C4 may also modulate the complex transmission of information between binding the effector and release of the DNA operator sequence by MphR. Although the random mutant library generated from the wild-type MphR may not have been screened exhaustively, it is notable that this library did not result in the rediscovery of the R122T or

R122V mutations. Together, these results emphasize that structure-guided mutagenesis and random mutagenesis were both significant in engineering the MphR selectivity (Figure 7) and this combination might be essential to create selective transcription factor-based biosensors.

Aside from the mutagenesis of the MphR transcription factor, the biosensor gene circuit itself was also engineered to improve its ability to discriminate CLA/ErA at low concentrations (Figure 7), thereby approximating conditions expected during initial stages of MT-directed evolution. This was accomplished by first replacing the RBS driving MphR expression with RBS variants identified in a previous study,²⁹ and then by consolidating the biosensor components into a single plasmid. A second plasmid was constructed that carried EryG as a mock MT to test the ability of the biosensor to discriminate CLA from ErA in the presence of the additional metabolic burden. Finally, both the biosensor components and the MT gene were combined into a single plasmid, pSENSE-M9C4-E7-MphA-EryG-GFP. To simulate the enzymatic conversion of CLA from ErA, different combinations of ErA and CLA were applied to the M9C4 single plasmid biosensor strain. This strain provided the ability to distinguish the equivalent of 2% conversion of ErA to CLA while providing a linear range of detection up to 100% conversion under the conditions tested. Notably, the wild-type sensor strain could not distinguish the simulated conversion across the entire ErA/CLA range tested. Presumably, reconfiguring the biosensor and MT plasmid constructs impacts the expression of the MphR transcription factor relative to the number of operator binding sites and effector molecules, thereby modulating the performance characteristics. Further engineering of the sensor system might be necessary to drive the identification of suitable biocatalysts at a higher load of the ErA starting material. In this case, additional rounds of error-prone PCR and screening are likely required to minimize the de-repression of MphR at high ErA concentrations (e.g., >10 μ M) so that the sensor maintains its CLA selectivity.

In summary, the combination of structure-guided and random mutagenesis followed by plasmid refactoring enabled the rapid development of a mutant MphR biosensor highly optimized for selective CLA detection. This is the first example of combining rational design and directed evolution to engineer repressor protein specificity toward different macrolides. The MphR variant M9C4 was confirmed to be an effective reporter for screening the potential ability of MTs to produce CLA from ErA. Indeed, this system is now poised to be coupled with libraries of MT variants to identify biocatalysts that can support the biosynthesis of CLA from ErA. For example, we anticipate that libraries of error-prone PCR variants can be generated from MTs involved in macrolide biosynthesis and cloned into the sensor strain. Such libraries can now be easily screened for CLA production by feeding in ErA. Similarly, the sensor strain could be leveraged to screen MTs from metagenomic libraries or other gene cluster collections. Potentially, this approach could result in the identification of an MT for the one-step, single-pot biosynthesis of CLA from ErA. Along with a recent example of the transcription factor engineering for reporting MTs,⁴⁰ our work sets the stage for a novel approach to engineering enzymes involved in natural product tailoring. In the broader context of biosensor engineering, this study represents a rare demonstration of the combination of semi-rational and directed

evolution approaches to provide remarkably selective transcription factor-based biosensors.

MATERIALS AND METHODS

Bacterial Strains, Plasmids, and Materials. The strains and plasmids used in this study are listed in [Supporting Information](#), Table S2. *E. coli* strains 10G (Lucigen) TOP10 (Invitrogen) were used for cloning and biosensor expression, respectively. Bacteria were grown in the Luria Broth (Fisher Scientific) supplemented with ampicillin (Fisher Scientific) and tetracycline (Fisher Scientific) as appropriate. ErA and CLA were obtained from Sigma-Aldrich. Each macrolide was prepared in dimethyl sulfoxide (DMSO) to a stock concentration of 0.5, 5, 50, or 500 μ M. DMSO and 96-deepwell plates were purchased from Fisher Scientific. All other chemicals were purchased from Sigma-Aldrich unless stated otherwise. PCR products were extracted with a Bio Basic Gel Extraction Kit. All enzymes for DNA manipulations were purchased from New England Biolabs. Plasmids were isolated using a plasmid miniprep kit from Bio Basic. All oligonucleotides were purchased from Integrated DNA Technologies. Clear and opaque flat-bottom 96-well plates were purchased from Greiner Bio-One. All other chemicals were of reagent grade or better.

Site-Directed Mutagenesis and Saturation Mutagenesis of MphR. Site-directed mutagenesis for the construction of each MphR variant was carried out using a QuikChange Mutagenesis Kit (Agilent) in a total volume of 40 μ L containing 100 ng of pMLGFPK 200 μ M dNTPs, 0.8 μ L of Phire Hot Start II DNA Polymerase (Thermo Scientific), and 0.5 mM each forward and reverse primer (entries 1–20, [Supporting Information](#), Table S3). Standard Phire thermocycling protocols were used with the site-directed mutagenesis protocol as described by the manufacturer's instructions. The reaction product was digested with *DpnI* for 1 h at 37 °C and transformed into chemical competent TOP10 cells. An aliquot of the overnight culture was plated onto LB agar plates supplemented with 100 μ g/mL ampicillin. The DNA sequences of plasmids from individual transformants confirmed that the correct mutation was obtained and that there were no spurious mutations except for M9C4 which had a non-coding mutation between the *mphR* promoter and its RBS ([Supporting Information](#), Table S1). Purified plasmids were transformed into TOP10 competent cells that carried other plasmids as necessary (e.g., pJZ12) and grown overnight in LB media supplemented with 3 μ g/mL tetracycline and 67 μ g/mL ampicillin. Glycerol stocks were prepared. For the construction of the single, double, and triple mutants derived from M9C4, the template pMLGFPK-R122T was used along with a suitable combination of primers (entries 21–26, see [Supporting Information](#), Table S3).

General Procedure for Microplate Screening of MphR Variants. Single colonies from mutant libraries in *E. coli* TOP10 were picked from LB agar plates and used to inoculate 500 μ L of LB media containing 67 μ g/mL ampicillin and 3 μ g/mL tetracycline in wells of a deep-well 96-well microplate. The cultures were incubated for 5 h at 37 °C and with shaking at 350 rpm. Then, 10 μ L of each culture was added to 490 μ L of LB media containing 67 μ g/mL ampicillin, 3 μ g/mL tetracycline, and either DMSO, 5 μ M ErA, or 5 μ M CLA. Plates were incubated overnight at 37 °C and with shaking at 350 rpm. The cultures were centrifuged at 5000g for 5 min and the cell pellet was resuspended in 1 mL of phosphate-buffered

saline (PBS). Then, 100 μL of the cell suspension was used for analyzing the optical density at 600 nm and fluorescence (ex 488 nm/em 515 nm) using a BioTek Hybrid Synergy 4. The fluorescence intensity was divided by the OD_{600} to yield a normalized GFP fluorescence value.

Dose–Response Analysis of Wild-Type and Variant MphR. Single colonies of the wild-type biosensor or variant MphR biosensor in *E. coli* TOP10 (that also included pJZ12 if necessary) were picked from LB agar plates and used to inoculate 500 μL of LB media containing 67 $\mu\text{g}/\text{mL}$ ampicillin and 3 $\mu\text{g}/\text{mL}$ tetracycline in wells of a deep-well 96-well microplate. The cultures were incubated for 5 h at 37 $^{\circ}\text{C}$ and with shaking at 350 rpm. Then, 10 μL of each culture was added to 490 μL of LB media containing 67 $\mu\text{g}/\text{mL}$ ampicillin, 3 $\mu\text{g}/\text{mL}$ tetracycline, and either ErA or CLA at concentrations between 0 and 200 μM . Plates were incubated overnight at 37 $^{\circ}\text{C}$ and with shaking at 350 rpm. The cultures were centrifuged at 5000g for 5 min and the cell pellet was resuspended in 1 mL of PBS. Next, 100 μL of the cell suspension was used for analyzing the optical density at 600 nm and fluorescence (ex 488 nm/em 515 nm) using a BioTek Hybrid Synergy 4. The fluorescence intensity was divided by the OD_{600} to yield a normalized GFP fluorescence value.

The data were fit to the Hill equation to derive the biosensor performance parameters

$$\text{GFP} = \text{GFP}_0 + \frac{\text{GFP}_{\text{max}} [\text{I}]^n}{K_{1/2}^n + [\text{I}]^n}$$

where GFP_0 is the normalized GFP expression in the absence of an inducer (i.e., GFP_{min}), GFP_{max} is the maximum observed normalized GFP fluorescence, $[\text{I}]$ is the effector concentration, $K_{1/2}$ is the effector concentration resulting in half-maximal induction, and n is the Hill coefficient describing biosensor cooperativity.

Error-Prone PCR Library Construction. A *KpnI* restriction site was inserted into pMLGFP by site-directed mutagenesis to generate pMLGFPK using the primers 29–30 (Supporting Information, Table S3). Error-prone PCR was performed using a GeneMorph II Random Mutagenesis Kit (Agilent Technologies) in a total volume of 50 μL using 2 ng of pMLGFPK or pMLGFPK-R122T, 0.8 mM dNTPs, 1 μL Mutazyme II DNA polymerase, 1.5 μL of the 10 mM forward primer, and 2.1 μL of the 10 mM reverse primer (entries 31–32, Supporting Information, Table S3). Thermocycling conditions were those recommended by the manufacturer's instructions. The PCR product was gel purified and double digested using *XbaI* and *KpnI* following standard protocols. The double digested product was ligated at 16 $^{\circ}\text{C}$ for 18 h into similarly treated pMLGFPK. The ligation product was ethanol precipitated and electroporated into *E. coli* 10G electro-competent cells and incubated overnight according to the manufacturer's instructions. An aliquot of the overnight culture was plated onto LB agar plates supplemented with 100 $\mu\text{g}/\text{mL}$ ampicillin. Randomly selected colonies were used to prepare plasmids for DNA sequencing, revealing on average 5.3 nucleotide mutations per MphR gene. The rest of the original overnight culture was grown as an overnight liquid culture in LB supplemented with 100 $\mu\text{g}/\text{mL}$ ampicillin. A copy of the library was made by the purification and storage of the plasmid DNA from an aliquot of the overnight culture. The rest of the overnight culture was stored as glycerol stocks.

Fluorescence-Activated Cell Sorting of Biosensor Libraries. The error-prone pMLGFPK plasmid libraries were transformed into TOP10 cells with plasmid pJZ12 and grown overnight in LB media supplemented with 67 $\mu\text{g}/\text{mL}$ ampicillin and 3 $\mu\text{g}/\text{mL}$ tetracycline. The cell culture was diluted 10-fold into fresh LB media and filtered through a 30 μm disposable Celtrix filter (Partec, Germany) and sorted on a Beckman Coulter MoFlo XDP cell sorter equipped with a 100 μm nozzle operating at 22 psi using a 488 nm excitation laser and measuring emission at 525 nm. Cells were collected in 1 mL of LB broth and incubated at 37 $^{\circ}\text{C}$ for 5 h with shaking at 270 rpm. A portion of the collected population was plated on LB agar supplemented with 67 $\mu\text{g}/\text{mL}$ ampicillin and 3 $\mu\text{g}/\text{mL}$ tetracycline, and the remaining population was grown overnight in LB media with 67 $\mu\text{g}/\text{mL}$ ampicillin and 3 $\mu\text{g}/\text{mL}$ tetracycline, and glycerol stocks were prepared. Putative hit variants from the error-prone PCR libraries were screened in triplicate in microplates according to the method described above.

Preparation of MphR Protein for Crystallization. The MphR M9C4 gene was amplified from pMLGFPK using primers CL2056 and CL2057 (entries 33–34, Supporting Information, Table S3), which added a *NcoI* site, 6x-His tag, and a Tobacco Etch Protease (TEV) recognition site on the N-terminus, and an *EcoRI* restriction site on the C-terminus. Gibson assembly was used to assemble the DNA fragment with the DNA pET28 vector fragment created using the primers CL2062 and CL2063 (entries 35–36, Supporting Information, Table S3). The protein expression was performed in *E. coli* BL21 (DE3) cells, which were grown to $\text{OD}_{600} = 0.8$ and then induced with a final concentration of 1 mM IPTG for 4 h at 37 $^{\circ}\text{C}$ in 2xYT media. Cells were harvested at 4000g, 10 min at 4 $^{\circ}\text{C}$. Media were removed and pelleted cells were washed in 30 mL nanopure water, then transferred to 50 mL centrifuge tubes. Cells were centrifuged again to remove the water and frozen at -80°C until ready to purify. Two 1 L frozen cell pellets were defrosted and resuspended in 30 mL of lysis buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole, pH 8) and 1 mM PMSF was added to each. Cells were lysed using a lysozyme (1 mg/mL), incubated on ice for 30 min, and then sonicated for 3×1.5 min. The cell debris was pelleted and the lysate poured onto the HisLink Ni resin and washed using 50 mM Tris, 300 mM NaCl, 80 mM imidazole, pH 8. The N-terminal His-TEV tagged MphR(A) was then eluted using 50 mM Tris, 300 mM NaCl, 500 mM imidazole, 10% glycerol, pH 8, 1 mM EDTA, and 1 mM DTT was added to each fraction. The protein was maintained in the same buffer, including the 10% glycerol for protein stability. Purified TEV (2 mL) at 5.675×10^{-5} M was added to the combined His-TEV-MphR(A) fractions. The protein mixture was digested and dialyzed (Fisherbrand, 6000–8000 MWCO tubing) into TEV working buffer: 50 mM Tris, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 10% glycerol, pH 8.0 at 4 $^{\circ}\text{C}$ for 1 h. In the last exchange, the buffer was switched to TEV working buffer minus the DTT and EDTA and allowed to digest and dialyze for 24 h. The final purified protein was obtained after flowing the protein mixture over a new HisLink Ni resin and collecting the flow-through (capturing the TEV and undigested protein).

Protein Crystallization, Data, and Refinement. Purified mutant MphR (~ 9.4 mg/mL) in 10 mM Tris, pH 8.0, 50 mM NaCl, 1 mM DTT was screened in sitting drops (200 nL) for crystallization against five commercial screens. CLA was added to a final concentration of 10 mM. The Wizard3 screen

(Rigaku) gave a large crystal within 2 weeks at 20 °C with an equal volume of the precipitant [20% PEG 3350, 0.2 M ammonium citrate dibasic, pH 5.5]. The crystal was cryoprotected briefly (15 s) in 30% PEG 3350 and 0.13 M ammonium citrate dibasic and immediately mounted in a liquid nitrogen vapor stream for data collection. Data were collected on an in-house Rigaku Micromax-007 diffractometer with a Dectris Eiger R 4M detector. Intensities to 2 Å resolution were processed using CrysAlisPro⁴¹ and indexed and scaled in space group $P2_12_12_1$ with Pointless⁴² and Aimless⁴³ in the CCP4 suite.⁴⁴ The structure was solved by molecular replacement using the structure of the MphR-ErA dimer complex (3frq) as a search model and Phaser⁴⁵ as implemented in Phenix.⁴⁶ Rigid body refinement of the MphR-CLA model was carried out followed by maximum likelihood parameter refinement in Phenix Refine with recursive rebuilding and solvent addition in Coot.⁴⁷ Some geometry restraints were applied to the CLA moiety. Table S4 of Supporting Information summarizes the data collection and refinement statistics. The coordinates for this structure have been deposited to the Protein Data Bank with accession code 6U18.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acssynbio.1c00151>.

Mutagenesis of MphR; construction of various plasmids; *in vivo* assay of EryG activity; and LC-HRMS analysis of ErA production; sequences of DNA constructs, strains, plasmids, and oligonucleotides used in this study; data collection and refinement statistics; crystal structure of MphR; characterization of site-directed MphR biosensor variants; FACS analysis; dose-response analysis; plasmid maps; LC-MS chromatograms; ErA production; and protein sequence of MphR M9C4 (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Gavin J. Williams – Department of Chemistry and Comparative Medicine Institute, NC State University, Raleigh, North Carolina 27695, United States; orcid.org/0000-0003-2172-9063; Email: gjwillia@ncsu.edu

Authors

Yiwei Li – Department of Chemistry, NC State University, Raleigh, North Carolina 27695, United States

Megan Reed – Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284, United States

H. Tonie Wright – Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia 23219, United States

T. Ashton Cropp – Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284, United States; Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia 23219, United States

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acssynbio.1c00151>

Author Contributions

G.J.W. and Y.L. conceived and designed this project. Y.L. carried out the experiments and analyzed the data. T.A.C., M.R., and H.T.W. designed and carried out the structural studies. Y.L., T.A.C., and G.J.W. interpreted the data. G.J.W., T.A.C., and Y.L. wrote the manuscript.

Notes

The authors declare the following competing financial interest(s): G.J.W. has published a patent application (US Patent Application No. 16/099,749) covering designer MphR variants and associated applications.

■ ACKNOWLEDGMENTS

This study was supported in part by the National Institutes of Health grant GM124112 (G.J.W. & T.A.C.) and the Thomas Lord Distinguished Professorship Endowment (G.J.W.). Crystallography facilities were funded by National Institutes of Health grant OD021756. M.R. acknowledges generous financial support from an Altria Graduate Research Fellowship. We are grateful to Dr. Faik Musayev of the Institute for Structural Biology, Drug Discovery, and Development for valuable assistance with crystallization and data collection.

■ REFERENCES

- (1) Zin, P. P. K.; Williams, G.; Fourches, D. SIME: Synthetic Insight-Based Macrolide Enumerator to Generate the VIB Library of 1 Billion Macrolides. *J. Cheminf.* **2020**, *12*, 23.
- (2) Drufva, E. E.; Hix, E. G.; Bailey, C. B. Site Directed Mutagenesis as a Precision Tool to Enable Synthetic Biology with Engineered Modular Polyketide Synthases. *Synth. Syst. Biotechnol.* **2020**, *5*, 62–80.
- (3) Hwang, S.; Lee, N.; Cho, S.; Palsson, B.; Cho, B.-K. Repurposing Modular Polyketide Synthases and Non-Ribosomal Peptide Synthetases for Novel Chemical Biosynthesis. *Front. Mol. Biosci.* **2020**, *7*, 87.
- (4) Kaneko, T.; Dougherty, T. J.; Magee, T. V. *Comprehensive Medicinal Chemistry II*; Elsevier, 2007; pp 519–566.
- (5) Dinos, G. P. The Macrolide Antibiotic Renaissance. *Br. J. Pharmacol.* **2017**, *174*, 2967–2983.
- (6) Adachi, T.; Morimoto, S. *Macrolide Antibiotics*; Birkhäuser, 2002; pp 53–72.
- (7) Chu, S. Y.; Deaton, R.; Cavanaugh, J. Absolute Bioavailability of Clarithromycin after Oral Administration in Humans. *Antimicrob. Agents Chemother.* **1992**, *36*, 1147–1150.
- (8) Peters, D. H.; Clissold, S. P. Clarithromycin. *Drugs* **1992**, *44*, 117–164.
- (9) Alvarez-Elcoro, S.; Enzler, M. J. The Macrolides: Erythromycin, Clarithromycin, and Azithromycin. *Mayo Clin. Proc.* **1999**, *74*, 613–634.
- (10) Hardy, D. J.; Swanson, R. N.; Rode, R. A.; Marsh, K.; Shipkowitz, N. L.; Clement, J. J. Enhancement of the *in Vitro* and *in Vivo* Activities of Clarithromycin against *Haemophilus Influenzae* by 14-Hydroxy-Clarithromycin, Its Major Metabolite in Humans. *Antimicrob. Agents Chemother.* **1990**, *34*, 1407–1413.
- (11) Heifets, L. B. Clarithromycin against *Mycobacterium Avium* Complex Infections. *Tubercle* **1996**, *77*, 19–26.
- (12) Ulmer, H.-J.; Beckerling, A.; Gatz, G. Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of *H. Pylori*: A Broad Data Review. *Helicobacter* **2003**, *8*, 95–104.
- (13) Fernandes, P.; Martens, E.; Bertrand, D.; Pereira, D. The Solithromycin Journey-It Is All in the Chemistry. *Bioorg. Med. Chem.* **2016**, *24*, 6420–6428.
- (14) Agouridas, C.; Denis, A.; Auger, J.-M.; Benedetti, Y.; Bonnefoy, A.; Bretin, F.; Chantot, J.-F.; Dussarat, A.; Fromentin, C.; D'Ambrières, S. G.; Lachaud, S.; Laurin, P.; Le Martret, O.; Loyau, V.; Tessot, N. Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-Oxoerythromycin Derivatives): A New Class of Anti-

bacterials Highly Potent Against Macrolide-Resistant and -Susceptible Respiratory Pathogens. *J. Med. Chem.* **1998**, *41*, 4080–4100.

(15) Bonnefoy, A.; Guitton, M.; Delachaux, C.; Le Priol, P.; Girard, A.-M. In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models. *Antimicrob. Agents Chemother.* **2001**, *45*, 1688–1692.

(16) Bryskier, A. Ketolides—Telithromycin, an Example of a New Class of Antibacterial Agents. *Clin. Microbiol. Infect.* **2000**, *6*, 661–669.

(17) Tran, M. P. Telithromycin: A Novel Agent for the Treatment of Community-Acquired Upper Respiratory Infections. *Bayl. Univ. Med. Cent. Proc.* **2017**, *17*, 475–479.

(18) Rodgers, W.; Frazier, A. D.; Champney, W. S. Solithromycin Inhibition of Protein Synthesis and Ribosome Biogenesis in *Staphylococcus Aureus*, *Streptococcus Pneumoniae*, and *Haemophilus Influenzae*. *Antimicrob. Agents Chemother.* **2013**, *57*, 1632–1637.

(19) Brunet, E.; Muñoz, D. M.; Parra, F.; Mantecón, S.; Juanes, O.; Rodríguez-Ubis, J. C.; Carmen Cruzado, M.; Asensio, R. Preparation of Clarithromycin. Selective 6-O-Methylation of the Novel Erythromycin A 9-O-(2-Pyrimidyl)Oxime. *Tetrahedron Lett.* **2007**, *48*, 1321–1324.

(20) Minas, W. *Microbial Processes and Products*; Humana Press, 2005; pp 65–90.

(21) Morimoto, S.; Misawa, Y.; Adachi, T.; Nagate, T.; Watanabe, Y.; Omura, S. Chemical modification of erythromycins. II. Synthesis and antibacterial activity of O-alkyl derivatives of erythromycin A. *J. Antibiot.* **1990**, *43*, 286–294.

(22) Morimoto, S.; Takahashi, Y.; Watanabe, Y.; Omura, S. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylethylerythromycins A. *J. Antibiot.* **1984**, *37*, 187–189.

(23) Fang, L.; Guell, M.; Church, G. M.; Pfeifer, B. A. Heterologous Erythromycin Production across Strain and Plasmid Construction. *Biotechnol. Prog.* **2017**, *34*, 271–276.

(24) Zhang, H.; Wang, Y.; Wu, J.; Skalina, K.; Pfeifer, B. A. Complete Biosynthesis of Erythromycin A and Designed Analogs Using *E. Coli* as a Heterologous Host. *Chem. Biol.* **2010**, *17*, 1232–1240.

(25) Davis, A. M.; Plowright, A. T.; Valeur, E. Directing Evolution: The next Revolution in Drug Discovery? *Nat. Rev. Drug Discovery* **2017**, *16*, 681–698.

(26) Fryszkowska, A.; Devine, P. N. Biocatalysis in Drug Discovery and Development. *Curr. Opin. Chem. Biol.* **2020**, *55*, 151–160.

(27) Mitchler, M. M.; Garcia, J. M.; Montero, N. E.; Williams, G. J. Transcription Factor-Based Biosensors: A Molecular-Guided Approach for Natural Product Engineering. *Curr. Opin. Biotechnol.* **2021**, *69*, 172–181.

(28) Zheng, J.; Sagar, V.; Smolinsky, A.; Bourke, C.; LaRonde-LeBlanc, N.; Cropp, T. A. Structure and Function of the Macrolide Biosensor Protein, MphR(A), with and without Erythromycin. *J. Mol. Biol.* **2009**, *387*, 1250–1260.

(29) Kasey, C. M.; Zerrad, M.; Li, Y.; Cropp, T. A.; Williams, G. J. Development of Transcription Factor-Based Designer Macrolide Biosensors for Metabolic Engineering and Synthetic Biology. *ACS Synth. Biol.* **2017**, *7*, 227–239.

(30) Cheng, Y.; Yang, S.; Jia, M.; Zhao, L.; Hou, C.; You, X.; Zhao, J.; Chen, A. Comparative Study between Macrolide Regulatory Proteins MphR(A) and MphR(E) in Ligand Identification and DNA Binding Based on the Rapid In Vitro Detection System. *Anal. Bioanal. Chem.* **2016**, *408*, 1623–1631.

(31) Möhrle, V.; Stadler, M.; Eberz, G. Biosensor-Guided Screening for Macrolides. *Anal. Bioanal. Chem.* **2007**, *388*, 1117–1125.

(32) Gardner, L.; Zou, Y.; Mara, A.; Cropp, T. A.; Deiters, A. Photochemical Control of Bacterial Signal Processing Using a Light-Activated Erythromycin. *Mol. Biosyst.* **2011**, *7*, 2554.

(33) Tang, S.-Y.; Fazelinia, H.; Cirino, P. C. AraC Regulatory Protein Mutants with Altered Effector Specificity. *J. Am. Chem. Soc.* **2008**, *130*, 5267–5271.

(34) Jha, R. K.; Chakraborti, S.; Kern, T. L.; Fox, D. T.; Strauss, C. E. M. Rosetta Comparative Modeling for Library Design: Engineering Alternative Inducer Specificity in a Transcription Factor. *Proteins: Struct., Funct., Bioinf.* **2015**, *83*, 1327–1340.

(35) Taylor, N. D.; Garruss, A. S.; Moretti, R.; Chan, S.; Arbing, M. A.; Cascio, D.; Rogers, J. K.; Isaacs, F. J.; Kosuri, S.; Baker, D.; Fields, S.; Church, G. M.; Raman, S. Engineering an Allosteric Transcription Factor to Respond to New Ligands. *Nat. Methods* **2015**, *13*, 177–183.

(36) Paulus, T. J.; Tuan, J. S.; Luebke, V. E.; Maine, G. T.; DeWitt, J. P.; Katz, L. Mutation and Cloning of EryG, the Structural Gene for Erythromycin O-Methyltransferase from *Saccharopolyspora Erythraea*, and Expression of EryG in *Escherichia Coli*. *J. Bacteriol.* **1990**, *172*, 2541–2546.

(37) Corcoran, J. W. S-Adenosylmethionine:Erythromycin C O-Methyltransferase. *Methods Enzymol.* **1975**, *43*, 487–498.

(38) Hossain, G. S.; Saini, M.; Miyake, R.; Ling, H.; Chang, M. W. Genetic Biosensor Design for Natural Product Biosynthesis in Microorganisms. *Trends Biotechnol.* **2020**, *38*, 797.

(39) Wu, Y.; Du, G.; Chen, J.; Liu, L. *Engineering of Microbial Biosynthetic Pathways*; Springer, 2020; pp 53–73.

(40) Kunjapur, A. M.; Prather, K. L. J. Development of a Vanillate Biosensor for the Vanillin Biosynthesis Pathway in *E. Coli*. *ACS Synth. Biol.* **2019**, *8*, 1958–1967.

(41) OD, Rigaku. *CrysAlisPro 40.64.42a*; Rigaku: Yarnton, Oxfordshire, England, 2015.

(42) Evans, P. R. An Introduction to Data Reduction: Space-Group Determination, Scaling and Intensity Statistics. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011**, *67*, 282–292.

(43) Evans, P. R.; Murshudov, G. N. How Good Are My Data and What Is the Resolution? *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2013**, *69*, 1204–1214.

(44) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 Suite and Current Developments. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011**, *67*, 235–242.

(45) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser Crystallographic Software. *J. Appl. Crystallogr.* **2007**, *40*, 658–674.

(46) Liebschner, D.; Afonine, P. V.; Baker, M. L.; Bunkóczi, G.; Chen, V. B.; Croll, T. I.; Hintze, B.; Hung, L.-W.; Jain, S.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R. D.; Poon, B. K.; Prisant, M. G.; Read, R. J.; Richardson, J. S.; Richardson, D. C.; Sammito, M. D.; Sobolev, O. V.; Stockwell, D. H.; Terwilliger, T. C.; Urzhumtsev, A. G.; Videau, L. L.; Williams, C. J.; Adams, P. D. Macromolecular Structure Determination Using X-rays, Neutrons and Electrons: Recent Developments in Phenix. *Acta Crystallogr., Sect. D: Struct. Biol.* **2019**, *75*, 861–877.

(47) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and Development of Coot. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 486–501.